Lifeline Biotechnologies Inc     (OTHER OTC: LBTT) Last Update: 9:00:00 AM ET Sep 23, 2004  
 
Lifeline in Discussions with Orthopedic Products Manufacturer; Company CEO Provides Update on Progress of Company

RENO, Nev., Sep 23, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (Pink: LBTT) today announced it is in discussions with a major manufacturer of unique orthopedic devices for the exclusive distribution of that company's state-of-the-art orthopedic products in North America. Lifeline currently markets, on an exclusive arrangement, disposable orthopedic devices manufactured by Inion in the North American markets.

"We continue to talk with companies that manufacture novel, disposable products that can complement our current line of orthopedic devices," said Frank Clark, CEO of Lifeline. "In a continuing effort to more rapidly build our sales in this growing area of health care, the company has initiated discussions with a number of companies and is currently evaluating a broad line of disposable patented soft goods that have been developed to address needs related to the protection of previously difficult-to-protect anatomical parts of the body."

In addition to the company's presence in the orthopedic market, Lifeline has a number of products in development for cancer diagnosis. The first of these, the MastaScope(TM), has been released in Europe and the Middle East. The MastaScope is a product that is used to detect breast cancer primarily found in nipple ducts, through the use of microendoscopy. This product is also being introduced this year into the Chinese marketplace.

Clark noted that Lifeline has made a significant investment in the continuing development of its state-of-the-art technology, a first warning system for the detection of cancerous tumors at their earliest stages in a non-invasive manner and the OvaScope(TM), a device that is intended to help doctors with diagnosis and treatment of ovarian cancer. "We look forward to the release of the MastaScope in the North American market in the next several months, and continued progress on our other products to diagnose and treat those cancers that primarily affect women," Clark said.

Doctors in Egypt, US and Japan to Submit Scientific Papers on MastaScope Results

RENO, Nev., Sep 23, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies (LBTT) today announced significant progress in the company's commercialization of its premiere product for early breast cancer detection. Dr. William Reeves, Lifeline's founder, provided a brief overview of the activities that have been carried out recently in connection with the MastaScope(TM).

"We have opened the Middle-Eastern territories following the signing of our distributor agreement with a company in Cairo, Egypt. Two teaching seminars have already been held in Cairo by Professor Kefah Mokbel, MB, BS, MS, FRCS, of St. George's Hospital and Medical College of London. Dr. Mokbel is also Professor at the Brunel Institute of Cancer Genetics & Pharmacogenomics and is one of Europe's leading breast cancer specialists," said Dr. Reeves.

He noted that at the latest seminar, held this past June, Professor Mokbel performed several breast procedures with the Lifeline MastaScope. These procedures were broadcast via closed circuit television to an audience of attending guest physicians. "The seminar was sponsored by the Egyptian National Cancer Institute specifically to demonstrate the MastaScope technology and to promote the concept of early breast cancer detection by means of microendoscopy."

Dr. Reeves went on to say that the final legalization by the Consulate General of The Arab Republic of Egypt (Certificate to Foreign Government) has been completed and delivered to New Horizon, Lifeline's Egyptian based distributor for the Middle East. The Certificate to Foreign Government is issued by the U.S. Food and Drug Administration and is required in order to allow the importation of United States products into foreign countries. New Horizon is now authorized to order MastaScopes from Lifeline and has several purchase orders pending.

Dr. Reeves noted that the magnification of tiny intraductal lesions were shown to be at least 60 times their actual size and 1/100th of the size presently detectable with magnetic resonance imaging or conventional mammography. "We strongly believe this technology will be viewed as a major breakthrough in early breast cancer detection technology as we educate and train greater numbers of doctors in this new detection technique," said Dr. Reeves.

Doctors to Submit Clinical Papers on MastaScope for Peer-Review Publication

Dr. Reeves commented that Professor Mokbel, Dr. Pedro Escobar of the Cleveland Clinic, and Dr. Matsunaga, a leading Japanese breast cancer specialist have prepared the first in a series of clinical papers on the MastaScope, which they plan to submit to peer-reviewed journals. "This type of medical publication is normal and necessary in the acceptance of any new medical concept or technology. In our case, the use of microendoscopy of the breast as an early cancer detection method, coupled with the results found with the use of the MastaScope is a topic that we believe will be of interest to the medical community. We are fortunate to have such imminent medical authorities involved in our project."

Dr. Reeves also noted other developments in connection with MastaScope, which included:

-- The Department of the Navy expressing interest and processing the necessary paperwork for the purchase of a MastaScope by a major Navy hospital. -- Professor Mokbel's appearance at a medical teaching seminar this coming December being hosted by Bethesda Naval Hospital for military surgeons interested in the use of the MastaScope in microendoscopic procedures of the breast. -- An initial five units are being prepared for shipment to China following the recent agreement with a new distributor for this area.

"We are confident that we are building awareness in the medical community for the MastaScope and believe that although each of these steps is a small one in and of itself, we are creating a significant pathway for future sales of our proprietary product," Dr. Reeves said.

what a market
when you think you found bottom bamm lower & lower... lbtt at .0039 is it bottom wish i knew.

quote:

---

Originally posted by Upside:
As much as you seem to dislike me Waveslider, I have to agree with you here. This looks primed for a run. Good luck.

---

no dislike upside just reading the cmkx thread drove me nut's... that thread is a saga in it's self..

now on lbtt i got in today beacuse QBID & LBTT HAVE BEEN TRENDING DOWN TOGETHER... QBID BROKE THAT TREND MAYBE

TAKING A CHANCE LIKE I DID AT .007 SOLD AT .0068 THAT TIME... WOULD LIKE TO SELL AT .007 THIS TIME FOR PROFIT....LOL NOT A LOSS

HARD CRUEL SUMMER HOPE IT'S OVER

WAVE

quote:

---

I hope you guys are right because I been sitting on this one for too long now - hey never know may be it will fly - at least they have something to sell....

---

They usually do what they say. When this goes up it can cover ground fast.

RENO, Nev., Sep 27, 2004 (BUSINESS WIRE) -- Lifeline Biotechnology, Inc. (Pink Sheets:LBTT) today announced that the company's executives will meet this week to plan a full-scale introduction of the MastaScope(TM) in the American market. The MastaScope is a medical diagnostic tool that provides minimally invasive visualization of breast tissues and abnormalities for patients with Pathological Nipple Discharge.

Dr. William Reeves, Lifeline's founder said: "This is a relatively new concept for detecting breast disease. Although our technology has been under development for more than a decade, few physicians in the world have performed the breast duct endoscopic procedure. For this reason, Lifeline depends on the advice and experience of doctors who are pioneers in training and educating other physicians, many of whom are eager to start offering this new medical procedure to their patients."

Dr. Reeves commented further, "Because we are dealing with new procedures and medical concepts, we must handle them in a manner similar to other medical breakthroughs. Open-heart surgery in the early 1970's, heart-bypass surgery and organ transplants all were amazing and viewed skeptically when they were first introduced. Today they are commonplace. Although the endoscopic procedure for the breast that our MastaScope enables is not as amazing a surgical feat as some of the aforementioned medical procedures, breast ductal endoscopy is certainly as critical and important. Professor Kefah Mokbel of St. George's Hospital and Medical School in London, a leading European breast cancer surgeon, found that breast ductal endoscopy can detect breast cancers when they are 1/100th the size of cancers seen on mammograms or magnetic resonance imaging. We are working to repeat that result with larger patient populations, and should it hold fast, as we believe it will, it will be a tremendous improvement in care for women throughout the world.

"I believe that breast duct endoscopy is here to stay and that this procedure will become an integral part of the war against breast cancer. Lifeline has every intention of working to lead the world with new innovative technologies," said Dr. Reeves.

He noted that as part of its plan for the initial introduction of the MastaScope in the US market, the company is currently in discussions with an eminent breast surgeon to become a part of the launch. The company expects to announce his name and background shortly.

quote:

---

Originally posted by WinsumLosesum:
Just thought I'd bring the LBTT thread to the top, for those who don't know how to find it.

Sheesh!

---

RENO, Nev., Oct 8, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (PINK:LBTT) today announced a $500,000 take-down on a $1 million private placement interim bridge funding, for stock that was completed last month.

"This financing is a positive step for Lifeline in that it enables the company to continue to aggressively pursue our strategies for growth in both of our divisions," said William Reeves, founder of Lifeline. "Although additional shares have been issued, investors in Lifeline should recognize that as with any company involved in medical or scientific developments, financing is the lifeblood that allows companies like Lifeline to move from research and development status to commercial, revenue producing entities."

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's two divisions, Orthopedics Instruments and Cancer Detection technologies, each deal with cutting edge innovation to assist practicing physicians to deliver quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning Systems for assisting in the early detection of ovarian cancer are continuing to be developed by the company. The Orthopedic division is the exclusive distributor for the Arthronet Shaver Blades in the US, Canada and Mexico, and also the exclusive distributor for the Inion bioabsorbable screw for the US and Canadian markets. More information is available at the company's website: www.lbti.com. The company does not endorse, nor is it connected in any way with any other websites found on the Internet.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe", "experts", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

SOURCE: Lifeline Biotechnologies, Inc.

quote:

---

Originally posted by wnycowboy:
In six months LBTT has been naked shorted (my opinion of course) from .03 to .003. I sure hope it can rebound in less time. Somebody please goose this puppy.

---

RENO, Nev., Oct 20, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (PINK: LBTT) today announced that it will effect a one for 150 reverse split of its common stock. Following the split, it is estimated that the company will have approximately 12.5 million shares outstanding, including those issued in connection with the recently announced funding. The number of authorized shares will be adjusted accordingly from five billion to 33.3 million. The reverse split will be effective for shareholders of record as of October 22, 2004. The reverse split also applies to preferred shares held by Lifeline management.

Jim Holmes, CFO, made the announcement noting, "While no one ever likes to see a reverse split, it is a pre-requisite for additional funding, which is required for us to continue our marketing and development activities. Furthermore, it is necessary for us to get our capital structure in position for our eventual move to a reporting exchange. We have a number of positive developments underway and these will strengthen the company's position in the marketplace. We believe the company can attract new investors with a more realistic capital structure. On behalf of Lifeline I want to apologize to our shareholders for the confusion that has surrounded this issue."

Holmes added that there are several milestones due to be completed in the next few months and early in 2005. These include:
-- The move from the pink sheets to the OTCBB once a Form 10K is
declared effective and a sponsoring brokerage firm is secured.

-- The continued sales of the company's MastaScope(TM) in the US
and worldwide.

-- The continued development of the OvaScope(TM) and Early
Warning System product lines.

-- Submission and publication of peer-reviewed science on the
company's proprietary products and technologies

"Lifeline has a very promising future. We are taking all of the steps that must be taken to build this company for the future. Although it can be difficult to judge the import of these steps in the short term, we believe that we are strengthening our company and positioning it for long term growth," said Holmes.

POMPANO BEACH, Fla., Oct 21, 2004 (BUSINESS WIRE) -- In BW5642 issued Oct. 21, 2004: First graph, first sentence of release, the ticker symbol for Lifeline Biotechnologies should read PINK:LBTT (sted OTC:LBTI).

The corrected release reads:

LIFELINE BIOTECHNOLOGIES ANNOUNCES THE DEVELOPMENT OF ITS FIRST INTRADUCTAL BIOPSY TOOL

Jonathan Reeves, President of Lifeline Biotechnologies (PINK:LBTT) announced today that the company has developed a companion biopsy tool for the MastaScope(TM). "We believe that this marks a breakthrough in breast cancer detection. Although still under clinical investigation, this tool will allow physicians to take tissue core biopsies under direct visualization from the abnormalities in the breast ducts that cause pathological nipple discharge."

According to Dr. Wm Reeves, Lifeline's founder, "This new biopsy tool should not be confused with ductal lavage, a method of sampling breast epithelium by means of cell washings." A news report issued on Tuesday, October 19, citing a study published in the Journal of the National Cancer Institute" called into question the benefits of ductal lavage as a means of detecting cancer in milk ducts before it shows up on mammograms.

"Some studies have shown that ductal lavage has had a low sensitivity for carcinoma in situ in breasts that contained invasive carcinomas. Unlike a cytological study of cell washings, the MastaScope (TM) biopsy device provides actual tissue from the abnormality in question. The physician knows that the tissue biopsy comes directly from the abnormality that he has under visualization and not from cells that have been scrubbed blindly from the ductal wall."

Reeves added, "Bloody nipple discharge is a significant clue in the detection of ductal carcinoma of the breast. In the past, pathologic diagnoses were obtained exclusively via excision, but this newly developed mammoscopic technique has been found to yield valuable information relating to the diagnosis of intraductal lesions."

quote:

---

Originally posted by thinkmoney:
no movement?

---

LBTN

quote:

---

Originally posted by thinkmoney:
get nothing on LBTN

---

My streamer shows no data, but that's what my whopping 66 shares are labeled in my portfolio this morning.

Best Bid: 0.17 (5000 shares)
Best Ask: 0.44 (5000 shares) *

Date/Time of Last Inside Change: 11:13 * Quoted on the Pink Sheets

Want real-time level two quotes in this security?
TRADE DATA Last Sale: 0.500
Change: +0.350

Percent Change: +233.33
Tick: Down
Daily High: 1.000 Daily Low: 0.150

Opening Price: 0.600 Volume: 22,976
Annual High: 8.250
Annual Low: 0.120
Dividend: 0.000 Earnings/Share: 0.00
Previous Close: 0.150 P/E ratio: N/A
Yield: 0.00
Beta Coefficient: 1.23
Last Trade Date/Time: 11:04
Trade data is delayed at least 15 minutes. Best Bid and Ask reflect prices between 8:00am and 4:00pm EST, after these hours the best Bid and Ask at 4:15pm is shown.